MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

Publisher: The Insight Partners

MindMed, the neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on March 3, 2020.

MindMed Co-Founder and Co-CEO JR Rahn said, "Our progress in the past few months clearly demonstrates the quality of our team and the pace at which we operate as a company. We are honored to pioneer the fast growing psychedelic inspired medicines industry alongside peers including COMPASS Pathways, ATAI Life Sciences and non-profits MAPs, USONA and the Heffter Institute. There is a very clear distinction of the caliber of organizations advancing clinical trials to develop disruptive medicines for mental health and addiction and we look forward to continually raising the bar for the entire space and patients."

In furtherance of its mission to discover, develop and deploy psychedelic inspired medicines the company and management have executed on the below selected opportunities since listing on March 3, 2020:

LSD (lysergic acid diethylamide) 

Experiential Therapies 

• Added an ongoing Phase 2 clinical trial evaluating high dose LSD for the treatment of anxiety disorders in collaboration with the University Hospital Basel's Liechti Lab.
• Initiated Project Lucy, a high dose LSD psychedelic assisted therapy drug commercial development program for the treatment of anxiety disorders, intending to undertake a Phase 2b human trial.
• Added and began treating patients in a Phase 2 clinical trial of LSD for Cluster Headaches in collaboration with University Hospital Basel's Liechti Lab.
• Filed a patent application for a LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session in collaboration with the University Hospital Basel's Liechti Lab.
• Acquired the exclusive license to 8 clinical trials and human safety studies of LSD at University Hospital Basel evaluating LSD.
• Filed a patent application and are developing technologies and analytics that seek to personalize LSD assisted therapy experiences for a specific patient in collaboration with University Hospital Basel Liechti Lab.

Microdosing Division 

• Entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for microdosing LSD in adult patients with ADHD intending to begin by the end of 2020.
• Appointed Principal Investigators for Phase 2a clinical trial for microdosing LSD Dr Kim Krupyers (Maastricht University) and Dr Matthias Liechti (University Hospital Basel).
• Added additional clinical trial site at University Hospital Basel for Phase 2a clinical trial at University Hospital Basel.

18-MC (Opioid Use Disorder Program)

• Initiated and began dosing of a Phase 1 human safety trial of our 18-MC program for Opioid Use Disorder in Australia in the midst of COVID-19.

MDMA (3,4-Methylenedioxymethamphetamine)

• Acquired the exclusive license to 9 completed clinical trials of MDMA at University Hospital Basel. Performing ongoing evaluation of data and opportunities to create new drug development programs to include MDMA
• Filed a patent application and are developing technologies and analytics that seek to personalize MDMA assisted therapy experiences for a specific patient in collaboration with University Hospital Basel Liechti Lab.

DMT (N,N-Dimethyltryptamine, active ingredient in Ayahuasca)

• Providing startup funding to Liechti Lab for a Phase 1 clinical trial of DMT testing various intravenous dosing regimens, expected to begin in Q4 of 2020 setting stage for future potential Phase 2a proof of concept trials

Corporate Development

• Appointed Johns Hopkins Professor and leading psychedelics researcher, Matt Johnson to its scientific advisory board